InVivoMAb anti-mouse PD-1 (CD279)（InVivoMAb鼠抗PD-1（CD279）单克隆抗体 ）
InVivoMAb anti-mouse PD-1 (CD279)（InVivoMAb鼠抗PD-1（CD279）单克隆抗体 ）
货号:BE0146-100MG
品名:InVivoMAb anti-mouse PD-1 (CD279)（InVivoMAb鼠抗PD-1（CD279）单克隆抗体 ）
品牌:BioXcell
规格:100mg
价格:请询价
产品详情介绍
产品描述
品牌：BioXcell
货号：BE0146-100MG
品名：抗小鼠PD-1（CD279）单克隆抗体（InVivoMAb）
规格：100mg
应用范围：体内阻断PD-1/PD-L信号通路、体外PD-1中和、免疫组化（冷冻）、流式细胞术、免疫荧光、Western blot等。
BioXcell InVivoMAb anti-mouse PD-1 (CD279) 是针对小鼠程序性死亡受体1（PD-1）的高特异性单克隆抗体，克隆号为29F.1A12。PD-1（CD279）是由Pdcd1基因编码的55-1 kDa跨膜蛋白，属于Ig超家族CD28家族成员，在T细胞、B细胞及髓系细胞表面表达，通过结合配体PD-L1/PD-L2抑制免疫应答。本产品采用重组PD-1-Ig融合蛋白免疫叙利亚仓鼠BKH细胞制备，经Protein G纯化，纯度>95%（SDS-PAGE验证），内毒素<2EU/mg，适用于体内及体外多种实验场景。
产品特点
1. 高特异性与亲和力：靶向小鼠PD-1的胞外结构域，阻断其与PD-L1/PD-L2的相互作用，中和效价经实验验证。
2. 实验兼容性广：支持体内阻断、体外中和、流式细胞术、免疫组化等多种应用，适配InVivoPure pH 7.0稀释缓冲液。
3. 稳定性优异：4°C保存无需冷冻，避免反复冻融导致的活性损失。
4. 低内毒素：严格生产工艺确保内毒素<2EU/mg，适用于活体实验。
5. 文献支持丰富：已发表于《Cancer Cell》《Nature》等期刊，涵盖肿瘤免疫、自身免疫疾病等研究领域。
储存条件
• 短期储存：4°C避光保存，避免冷冻。
• 长期保存：分装后-20°C冻存，建议1年内使用。
• 运输条件：干冰运输，避免高温及反复冻融。
工作原理
PD-1通过结合PD-L1/PD-L2传递抑制性信号，抑制T细胞活化及细胞因子分泌，介导免疫逃逸。本抗体通过竞争性结合PD-1的胞外结构域，阻断其与配体的相互作用，从而恢复T细胞抗肿瘤活性。在黑色素瘤、结肠癌等小鼠模型中，该抗体可显著抑制肿瘤生长并延长生存期。
解决实验中哪些问题
1. 肿瘤免疫逃逸研究：模拟PD-1/PD-L1通路阻断效应，验证免疫检查点抑制剂疗效。
2. 自身免疫疾病机制探索：研究PD-1在维持外周耐受中的作用，如PD-1敲除小鼠的扩张型心肌病模型。
3. 移植排斥调控：评估抗体对移植物抗宿主病（GVHD）的干预效果。
4. 化疗/放疗增敏：联合传统疗法增强抗肿瘤免疫应答，如黑色素瘤模型中与抗CTLA-4联用。
5. 生物标志物开发：通过流式细胞术检测肿瘤微环境中PD-1+ T细胞比例，指导个性化治疗。
使用方法
1. 体内实验（小鼠模型）
• 剂量：推荐5-20 mg/kg，具体根据实验模型调整。
• 给药途径：静脉注射或腹腔注射。
• 实验设计：肿瘤接种后第3天开始给药，每周2次，持续3-4周。联合用药时，需验证抗体与化疗/放疗的时间窗兼容性。
2. 体外实验
• 流式细胞术：
• 细胞悬液（1×10^6 cells/mL）与抗体（1-10 μg/mL）孵育30分钟，避光。
• 洗涤后用荧光标记二抗检测PD-1表达。
• Western Blot：
• 蛋白提取物（20-50 μg）经SDS-PAGE分离后，转膜并封闭。
• 抗体稀释比例1:500-1:1000，4°C孵育过夜，HRP标记二抗检测。
3. 免疫组化（冷冻切片）
• 切片脱蜡后PBS洗涤，3% H2O2灭活内源性过氧化物酶。
• 抗体稀释比例1:100-1:200，室温孵育1小时，DAB显色。
常见问题与解决方案
问题1：抗体效价低或无信号
• 原因：储存温度不当或反复冻融。
• 解决：分装后-20°C保存，避免反复冻融；验证稀释比例。
问题2：非特异性结合
• 原因：样本中Fc受体干扰。
• 解决：加入Fc受体阻断剂，优化封闭条件。
问题3：Western Blot背景高
• 原因：膜未充分封闭或抗体浓度过高。
• 解决：延长封闭时间至1小时，降低一抗浓度至1:1000。
问题4：流式检测结果不稳定
• 原因：细胞表面PD-1表达水平低。
• 解决：优化固定/透化步骤。
问题5：实验重复性差
• 原因：抗体批次差异或操作误差。
• 解决：使用同种型对照校准结果，严格记录实验参数。
免责声明
1. 本产品仅限科研用途，不可用于人体诊断或治疗。
2. 实验结果可能因样本类型、操作条件及仪器差异而波动，建议预实验验证。
3. 本公司提供技术支持，但不对用户自行修改实验方案导致的后果负责。
4. 产品性能参数基于内部测试，实际应用中需根据实验需求调整。
5. 本文内容基于品牌公开资料及行业常规信息整理，仅个人观点，具体以品牌信息文档为准。
⚡TBioXcell热卖产品
|
货号 |
品名 |
规格 |
品牌 |
|
BE0146-100MG |
InVivoMAb anti-mouse PD-1 (CD279) |
100mg |
BioXcell |
|
BE0146-50MG |
InVivoMab anti-mouse PD-1 (CD279) |
50mg |
BioXcell |
|
BP0146-100MG |
InVivoPlus anti-mouse PD-1 (CD279) |
100mg |
BioXcell |
|
BE0146-5MG |
InVivoMab anti-mouse PD-1 (CD279) |
5mg |
BioXcell |
|
BE0016-2-5MG |
InVivoMab anti-mouse CD40 |
5mg |
BioXcell |
|
BE0001-1-1mg |
InVivoMAb anti-mouse CD3ε |
1mg |
BioXcell |
|
BE0045-1MG |
InVivoMAb anti-mouse IL-4 |
1mg |
BioXcell |
|
BE0101-50mg |
InVivoMAb anti-mouse PD-L1 (B7-H1) |
50mg |
BioXcell |
|
BE0101-100ＭG |
InVivoMAb anti-mouse PD-L1 (B7-H1) |
100ＭG |
BioXcell |
|
BE0055-1MG |
InVivoMAb anti-mouse IFNγ |
1mg |
BioXcell |
|
IP0070-50ML |
pH 7.0 Dilution Buffer |
50ml |
BioXcell |
|
BE0101-5MG |
InVivoMAb anti-mouse PD-L1 (B7-H1) |
5MG |
BioXcell |
|
BP0146-50mg |
InVivoPlus anti-mouse PD-1 (CD279) |
50mg |
BioXcell |
|
BE0235-1MG |
InVivoMAb anti-human IFNγ |
1mg |
BioXcell |
|
BP0146 |
InVivoPlus anti-mouse PD-1 (CD279) |
5mg |
BioXcell |
|
BP0001-1 |
InVivoPlus anti-mouse CD3ε |
5mg |
BioXcell |
|
BP0101 |
InVivoPlus anti-mouse PD-L1 (B7-H1) |
5MG |
BioXcell |
|
BE0146-25MG |
InVivoMab anti-mouse PD-1 (CD279) |
25mg |
BioXcell |
|
BE0016-2 |
InVivoMab anti-mouse CD40 |
50mg |
BioXcell |
|
BE0240-1MG |
InVivoMab anti-human IL-4 |
1mg |
BioXcell |
|
BE0164-50mg |
InVivoMAb anti-mouse CTLA-4 (CD152) Clone：9D9 |
50mg |
BioXcell |
|
BP0131 |
InVivoPlus anti-mouse CTLA-4 (CD152) |
50 mg |
BioXcell |
|
BE0004-1-5MG |
InVivoMAb anti-mouse CD8α |
5mg |
BioXcell |
|
BE0047-1mg |
InVivoMAb anti-mouse IL-6R |
1mg |
BioXcell |
|
BE0320-50MG |
InVivoMAb anti-mouse Ly6G/Ly6C |
50mg |
BioXcell |
|
BE0016-2-25MG |
InVivoMab anti-mouse CD40 |
25mg |
BioXcell |
|
BP0061-50MG |
InVivoPlus anti-mouse CD8α |
50mg |
BioXcell |
|
BE0089-100MG |
InVivoMab rat IgG2a isotype control |
100mg |
BioXcell |
|
BE0098-5MG |
InVivoMAb recombinant Flt-3L-Ig (hum/hum) |
5mg |
BioXcell |
|
BE0034-5MG |
InVivoMab anti-mouse LPAM-1 (Integrin α4β7) |
5mg |
BioXcell |
|
BE0031 |
InVivoMAb anti-mouse OX40 (CD134) |
25mg |
BioXcell |
|
BE0117-1MG |
InVivoMAb anti-mouse CD8α |
1mg |
BioXcell |
|
BE0060-50mg |
InVivoMAb anti-mouse VEGFR-2 |
50mg |
BioXcell |
|
BP0164 |
InVivoPlus anti-mouse CTLA-4 (CD152) |
50mg |
BioXcell |
|
BE0075-1-5MG |
InVivoMab anti-mouse Ly6G |
5MG |
BioXcell |
|
BE0173-25MG |
InVivoMab anti-mouse IL-17A |
25mg |
BioXcell |
|
BP0164-50MG |
InVivoPlus anti-mouse CTLA-4 (CD152) |
50mg |
BioXcell |
|
BE0090 |
InVivoMAb rat IgG2a isotype control, anti-trinitrophenol |
25mg |
BioXcell |
|
BE0089 |
InVivoMAb rat IgG2a isotype control, anti-trinitrophenol |
50mg |
BioXcell |
|
BP0075-25mg |
InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1) |
25mg |
BioXcell |
|
BP0213 |
InVivoPlus anti-mouse CSF1R (CD115) |
25mg |
BioXcell |
|
BP0004-1-25MG |
InVivoPlus anti-mouse CD8α |
25mg |
BioXcell |
|
BP0036-25MG |
InVivoPlus anti-mouse NK1.1 |
25mg |
BioXcell |
|
BP0003-1- 25mg |
InVivoPlus anti-mouse CD4 |
25MG |
BioXcell |
|
BE0394-1MG |
InVivoMAb anti-mouse IL-25 |
1mg |
BioXcell |
|
BE0016-2-1MG |
InVivoMab anti-mouse CD40 |
1 mg |
BioXcell |
|
BE0275-100MG |
InVivoMab anti-mouse TIM-3 (CD366) |
100mg |
BioXcell |
|
BE0001-1FAB-25MG |
InVivoMAb anti-mouse CD3ε F(ab')2 fragment |
25mg |
BioXcell |
|
BE0164-100MG |
InVivoMab anti-mouse CTLA-4 (CD152) |
100MG |
BioXcell |
|
SIM0022-5MG |
InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) |
5mg |
BioXcell |
|
BE0034 |
InVivoMAb anti-mouse LPAM-1 (Integrin α4β7) |
5mg |
BioXcell |
|
BE0058-1MG |
InVivoMab anti-mouse TNFα |
1mg |
BioXcell |
|
BE0046-1mg |
InVivoMAb anti-mouse IL-6 |
1mg |
BioXcell |
|
SIM0014-1MG |
InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) |
1mg |
BioXcell |
|
BE0049-5MG |
InVivoMAb anti-mouse IL-10 |
5MG |
BioXcell |
|
BP0089-50mg |
InVivoPlus rat IgG2a isotype control, anti-trinitrophenol |
50mg |
BioXcell |
|
BE0117-25MG |
InVivoMab anti-mouse CD8α |
25mg |
BioXcell |
|
BE0117-5MG |
InVivoMab anti-mouse CD8α |
5mg |
BioXcell |
|
BE0223-25MG |
InVivoMab anti-mouse CD8β (Lyt 3.2) |
25mg |
BioXcell |
|
BE0088-25MG |
InVivoMab rat IgG1 isotype control (anti-HRP) |
25mg |
BioXcell |
|
BE0089-25MG |
Isotype Control, anti- Trinitrophenol |
25mg |
BioXcell |
|
BE0214-5MG |
InVivoMab anti-mouse Thy1.1 (CD90.1) |
5mg |
BioXcell |
|
BE0061-25MG |
InVivoMab anti-mouse CD8α |
25mg |
BioXcell |
|
BE0033-2-5MG |
InVivoMAb anti-mouse PD-1 (CD279) |
5mg |
BioXcell |
|
BE0023-5MG |
InVivoMAb anti-human CD71 |
5MG |
BioXcell |
|
BE0119 |
InVivoMAb anti-mouse CD4 |
5mg |
BioXcell |
|
BE0280-25MG |
InVivoMAb anti-mouse c-Kit (CD117) |
25mg |
BioXcell |
|
BE0046-25MG |
InVivoMab anti-mouse IL-6 |
25mg |
BioXcell |
|
BE0001-1-100MG |
InVivoMab anti-mouse CD3ε |
100mg |
BioXcell |
|
BE0002-50MG |
InVivoMab anti-mouse CD3 |
50mg |
BioXcell |
|
BE0086-5mg |
InVivoMAb mouse IgG2b isotype control, unknown specificity |
5mg |
BioXcell |
|
BE0173-5MG |
InVivoMab anti-mouse IL-17A |
5mg |
BioXcell |
|
BE0146-1mg |
InVivoMAb anti-mouse PD-1 (CD279) |
1mg |
BioXcell |
|
BE0298-50MG |
InVivoMAb anti-mouse CD122 (IL-2Rβ) |
50mg |
BioXcell |
|
BE0311-5mg |
InVivoMAb anti-mouse CD317 (BST2, PDCA-1) |
5mg |
BioXcell |
|
BE0033-2-1MG |
InVivoMab anti-mouse PD-1 (CD279) |
1mg |
BioXcell |
|
BE0191-5MG |
InVivoMab anti-mouse RANKL (CD254) |
5mg |
BioXcell |
|
BE0191-25MG |
InVivoMab anti-mouse RANKL (CD254) |
25mg |
BioXcell |
|
BE0191-50MG |
InVivoMab anti-mouse RANKL (CD254) |
50mg |
BioXcell |
|
BE0399-100MG |
InVivoMAb anti-mouse VEGF-A |
100mg |
BioXcell |
|
BE0001-1FAB50MG |
InVivoMab anti-mouse CD3ε F(ab')2 fragment |
50mg |
BioXcell |
|
BE0399-50MG |
InVivoMAb anti-mouse VEGF-A |
50mg |
BioXcell |
|
BP0012-5MG |
InVivoPlus anti-mouse CD25 (IL-2Rα) |
5mg |
BioXcell |
|
BP0307-5MG |
InVivoPlus anti-mouse CD16/CD32 |
5mg |
BioXcell |
|
SIM0002-100MG |
InVivoSIM anti-human EGFR (Cetuximab Biosimilar) |
100mg |
BioXcell |
|
BE0323-5MG |
InVivoMAb anti-mouse TL1A (TNFSF15) |
5mg |
BioXcell |
|
BE0119-50MG |
InVivoMAb anti-mouse CD4 |
50mg |
BioXcell |
|
BE0083-25MG |
InVivoMAb mouse IgG1 isotype control, unknown specificity |
25mg |
BioXcell |
|
BP0016-2-5MG |
InVivoPlus anti-mouse CD40 |
5mg |
BioXcell |
|
CP174-1mg |
RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
1mg |
BioXcell |
|
BE0375-5MG |
InVivoMAb anti-human EGFR |
5mg |
BioXcell |
|
BE0003-1-25MG |
InVivoMAb anti-mouse CD4 |
25mg |
BioXcell |
|
BE0164-1MG |
InVivoMAb anti-mouse CTLA-4 (CD152) |
1mg |
BioXcell |
|
BE0173-50MG |
InVivoMAb anti-mouse IL-17A |
50mg |
BioXcell |
|
SIM0004-1MG |
InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) |
1mg |
BioXcell |
|
BE0356-25MG |
InVivoMAb anti-mouse CD20 |
25mg |
BioXcell |
|
BE0164-25MG |
InVivoMAb anti-mouse CTLA-4 (CD152) |
25MG |
BioXcell |
|
BE0043-1-1MG |
InVivoMAb anti-mouse IL-2 |
1mg |
BioXcell |
|
BP0086-50MG |
InVivoPlus mouse IgG2b isotype control, unknown specificity |
50mg |
BioXcell |
|
BP0297-50MG |
InVivoPlus human IgG1 isotype control |
50mg |
BioXc |